Zeyu Wu

Dr. Zeyu Wu


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 March 2026 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
MLMingqi Liu
Mingqi Liu
TYTiantian Yu
Tiantian Yu
UNUlipan Nurlan
Ulipan Nurlan
ZWZeyu Wu
Zeyu Wu
JZJin Zhao
Jin Zhao
This review provides a comprehensive synthesis of the ethnopharmacological uses, modern applications, phytochemistry, and pharmacological mechanisms of Hippophae rhamnoides L . ( H. rhamnoides ) It begins by detailing its foundational role in traditional medical systems within its native range, including Tibetan, Mongolian, and Chinese medicine, as well as its broader Eurasian ethnobotanical applications. The work then systematically outlines the plant’s diverse modern utilizations in nutraceuticals, cosmeceuticals, pharmaceuticals, and environmental remediation. A thorough organ-specific analysis of its phytochemical architecture that identifies key bioactive constituents in berries, seeds and leaves links to demonstrated pharmacological effects, including hepatoprotective, anti-inflammatory, cardioprotective and neuroprotective activities. A critical discussion on the potential interference of Pan-Assay Interference Compounds (PAINS) is included to provide a necessary caveat for interpreting bioactivity data. Finally, the review identifies persistent challenges including phytochemical standardization and the translational gap between preclinical and clinical research, and proposes future research directions focused on rigorous clinical trials, mechanistic studies and sustainable exploitation within a circular bioeconomy framework.

10 December 2025 in Frontiers in Microbiology
Verified
Journal Article
Open access
PDF file
JSJie Song
Jie Song
MLMingqi Liu
Mingqi Liu
YYYizinigaer Yasen
Yizinigaer Yasen
YZYing Zhao
Ying Zhao
ZWZeyu Wu
Zeyu Wu
JZJin Zhao
Jin Zhao
Introduction: Dental caries is driven by dysbiosis of oral biofilms. Conventional antibiotics easily disrupt oral commensal balance, creating an urgent need for natural, non-antibiotic agents that can target cariogenic biofilms without causing ecological collapse. Methods: The antimicrobial and antibiofilm efficacy of Naringin was evaluated in vitro against planktonic and biofilm states of Streptococcus mutans, Streptococcus sobrinus, Streptococcus sanguinis (mono-species), and their multi-species consortium. Minimum inhibitory/bactericidal concentrations (MIC/MBC) and minimum biofilm inhibitory/reduction concentrations (MBIC/MBRC) were determined. Effects on acid production, extracellular polysaccharide (EPS) synthesis, and bacterial adhesion to hydroxyapatite (HAP) were mechanistically investigated. In vivo , a rat caries model induced by the multi-species consortium was topically treated with Naringin (2 × MIC, MIC, 1/2 × MIC) for 4 weeks. Caries lesions were evaluated using Keyes scoring and micro-computed tomography. Oral microbiota, serum biochemistry, and histopathology were analyzed for safety assessment. Results: Naringin exhibited potent, concentration-dependent antimicrobial activity. MICs were 1.00 mg/mL for S. mutans and S. sanguinis , 0.50 mg/mL for S. sobrinus , and 0.50 mg/mL for the multi-species consortium. Naringin at MBIC (2 mg/mL for multi-species) significantly disrupted biofilm architecture, reduced viable bacteria, and inhibited EPS synthesis. It maintained biofilm pH above 5.5 (the critical threshold for enamel demineralization), inhibited lactate production, and reduced multi-species bacterial adhesion to HAP by 68.3% at MIC. In vivo , Naringin (MIC) significantly reduced Keyes scores on smooth and sulcal surfaces by over 60%, preserved enamel integrity, and rebalanced the oral microbiota without inducing mucosal irritation or systemic toxicity. Discussion: Naringin, a natural non-antibiotic agent, effectively inhibits the “adhesion-biofilm-acid-EPS” cascade of multi-species cariogenic biofilms. Its selective efficacy against pathogens and favorable in vivo safety profile position it as a promising ecological agent for caries prevention by addressing oral dysbiosis at its root.

20 November 2025 in Archives of Oral Biology
Verified
Journal Article
Open access
YXYuning Xia
Yuning Xia
CSChao Shan
Chao Shan
ZWZeyu Wu
Zeyu Wu
JZJin Zhao
Jin Zhao
This study aims to investigate the effects and mechanisms of tetramethoxyluteolin (TML), a bioactive compound in mulberry leaves, on jaw bone marrow mesenchymal stem cells (JBMMSCs) in a periodontitis microenvironment. Network pharmacology and molecular docking were used to identify mulberry leaves' active constituents and their targets in periodontitis treatment. An inflammatory model was established in JBMMSCs using Porphyromonas gingivalis-lipopolysaccharide (5 μg/mL). TML's optimal concentration was determined via CCK-8 and ELISA. Osteogenic differentiation, inflammatory markers, and NF-κB pathway activity were assessed using ALP/ARS staining, RT-PCR, and Western blot (WB). A rat model of ligature-induced periodontitis was established, and TML's effects were evaluated through histopathological staining, micro-CT, RT-PCR, and WB. JBMMSCs from each animal experimental group were isolated for in vitro osteogenic validation. Mechanisms were clarified by comparing TML with the NF-κB inhibitor BAY11-7082. TML was identified as the key constituent targeting NF-κB and inflammatory mediators (IL-6, IL-1β, TNF-α). 5 μM TML significantly suppressed inflammatory cytokines, promoted osteogenic differentiation, and inhibited NF-κB activation in JBMMSCs. In rats, 30 mg/kg TML markedly reduced inflammation and alveolar bone loss, showing efficacy comparable to indomethacin, and JBMMSCs from TML-treated groups exhibited enhanced osteogenesis. TML's inhibition of NF-κB was similar to BAY11-7082. TML reduces periodontal inflammation and enhances the osteogenic potential of JBMMSCs by inhibiting the NF-κB pathway, providing a novel strategy for periodontitis-related bone regeneration.

14 August 2026 in Frontiers in Microbiology
Verified
Journal Article
Open access
PDF file
HDHongzhao Ding
Hongzhao Ding
YYYizinigaer Yasen
Yizinigaer Yasen
JSJie Song
Jie Song
WFWenjun Fan
Wenjun Fan
ZWZeyu Wu
Zeyu Wu
JZJin Zhao
Jin Zhao
Dental caries remains a prevalent global health burden driven by dysbiosis of the biofilm microbiome. Antimicrobial peptides (AMPs), characterized by a low risk of resistance development and immunomodulatory potential, have emerged as promising alternatives to conventional antimicrobials; however, their clinical translation is still constrained by physiological instability, cytotoxicity, limited oral substantivity, and substantial regulatory and economic barriers. This review systematically summarizes recent advances in the mechanisms of action, rational design, and translational strategies of AMPs for the prevention and management of dental caries. The article first outlines updated mechanistic concepts, highlighting a shift from the classical stable pore-forming model toward transient water channel formation and lipid flip-flop models, and further discusses microbiome-oriented ecological modulation strategies aimed at preserving beneficial commensals and suppressing cariogenic dysbiosis. In addition, structure–activity relationships are examined in depth, with emphasis on how diverse optimization approaches can balance peptide activity, toxicity, stability, selectivity, and manufacturability. The review also delineates the major barriers that impede clinical translation, including production cost, GMP-compatible manufacturing, batch consistency, delivery format, and regulatory definability. Potential strategies are discussed, including molecular farming in plant bioreactors, recombinant or synthetic production platforms, covalent immobilization, in situ biomimetic systems, and pH-responsive delivery systems for improving local bioavailability within cariogenic microenvironments. Finally, we emphasize that most current evidence remains preclinical and that no generalizable clinical framework for AMP-based caries prevention has yet been established. Future development should integrate mechanism-guided design, microbiome-level evaluation, standardized safety and efficacy endpoints, scalable manufacturing, and controlled clinical validation.